… An in vitro drug release study was performed in order to determine the release behavior of
the Erlotinib HCl from nanoparticles. For this study, freeze-dried nanoparticles of Erlotinib HCl …

… Presence of food shows the variability in pharmacokinetics of erlotinib especially in absorption.
The present study is aimed at developing solid lipid nanoparticles for Erlotinib HCl and …

… In the RECEL study, we investigated the efficacy and tolerability of erlotinib versus
chemotherapy (etoposide/cisplatin), both with concurrent RT, for unresectable stage III NSCLC …

… Aim: This study aimed to formulate erlotinib hydrochloride (ERT-HCL)-loaded chitosan (CS)
and poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) using Quality-by-Design (QbD) …

… study was that it was a clinical trial with small sample size. Also, since many trials showed that
the efficacy of erlotinib … III studies, and thus the expectations for the combination therapy of …

… The aim of this research was to formulation and evaluation of Injectable microspheres of
Erlotinib Hydrochloride. Erlotinib HCL Injectable microspheres were prepared by O/W emulsion …

… Nine studies comprising 1698 patients with NSCLC were included in this meta-analysis, of
whom 850 were treated with erlotinib plus bevacizumab, and 848 with erlotinib. The erlotinib …

… of hydrochloric acid (HCl), sodium hydroxide (NaOH), and hydrogen peroxide (H 2 O 2 ) [12,13],
the impact of formulation change needs to be assessed. As a result, this study was …

… We conducted a randomized exploratory phase II multicenter trial that evaluated the
efficacy and tolerability of bevacizumab (A) and bevacizumab/erlotinib (AE) as first-line …

… Moreover, little research is available on adverse events associated with combining erlotinib
and bevacizumab. To resolve these issues, we conducted a meta-analysis and systematic …